MedPacto, Inc. (235980.KQ)
- Previous Close
3,185.00 - Open
3,185.00 - Bid 3,000.00 x --
- Ask 3,480.00 x --
- Day's Range
3,105.00 - 3,245.00 - 52 Week Range
2,750.00 - 9,910.00 - Volume
62,772 - Avg. Volume
223,984 - Market Cap (intraday)
106.283B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 14, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea.
www.medpacto.comRecent News: 235980.KQ
View MorePerformance Overview: 235980.KQ
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 235980.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 235980.KQ
View MoreValuation Measures
Market Cap
106.28B
Enterprise Value
52.75B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.84
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-17.83%
Return on Equity (ttm)
-30.20%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-19.15B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
55.48B
Total Debt/Equity (mrq)
3.36%
Levered Free Cash Flow (ttm)
-21.45B